Great Point Partners LLC Has $7.53 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Great Point Partners LLC decreased its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 63.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 275,000 shares of the company’s stock after selling 482,929 shares during the period. Dianthus Therapeutics makes up approximately 2.2% of Great Point Partners LLC’s holdings, making the stock its 18th largest holding. Great Point Partners LLC’s holdings in Dianthus Therapeutics were worth $7,530,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DNTH. Quest Partners LLC raised its position in shares of Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the period. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $112,000. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics in the 2nd quarter valued at about $236,000. WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics during the second quarter worth approximately $265,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Dianthus Therapeutics during the second quarter worth approximately $334,000. 47.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DNTH shares. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Raymond James raised their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Up 1.7 %

Shares of Dianthus Therapeutics stock opened at $23.86 on Wednesday. The company has a market capitalization of $706.18 million, a price-to-earnings ratio of -9.54 and a beta of 1.84. The firm’s 50-day moving average price is $26.91 and its two-hundred day moving average price is $26.61. Dianthus Therapeutics, Inc. has a 12-month low of $6.58 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.